VRTX Overview
Upcoming Projects (VRTX)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (VRTX)
-
A Second Opinion: An updated look at the potential of Vertex Phamaceuticals' “Vanza Triple” (vanzacaftor/tezacaftor/deutivacaftor) in patients with cystic fibrosis
Ticker: VRTX
Executed On: Dec 05, 2024 at 09:00 AM EST -
Second View: Discussing the recent FDA acceptance for Vertex Pharmacuetical's Suzetrigine, an investigational oral, selective NaV1.8 pain signal inhibitor.
Ticker: VRTX
Executed On: Nov 26, 2024 at 10:30 AM EST -
Discussing the recent FDA acceptance for Vertex Pharmacuetical's Suzetrigine, an investigational oral, selective NaV1.8 pain signal inhibitor.
Ticker: VRTX
Executed On: Nov 22, 2024 at 01:45 PM EST -
An updated look at the potential of Vertex Phamaceuticals' “Vanza Triple” (vanzacaftor/tezacaftor/deutivacaftor) in patients with cystic fibrosis
Ticker: VRTX
Executed On: Nov 14, 2024 at 01:00 PM EST -
A Third Look: Discussing the future use of Exparel in light of the recent patent coverage loss and the FDA approval of an exparel generic
Tickers: PCRX, VRTX
Executed On: Sep 25, 2024 at 10:30 AM EDT -
A Second Look: Discussing the future use of Exparel in light of the recent patent coverage loss and the FDA approval of an exparel generic
Tickers: PCRX, VRTX
Executed On: Sep 12, 2024 at 12:00 PM EDT -
Discussing how payers are strategizing pricing and reimbursement for cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease.
Tickers: VRTX, BLUE, CRSP
Executed On: Sep 11, 2024 at 04:00 PM EDT -
Discussing the future use of Exparel in light of the recent patent coverage loss and the FDA approval of an exparel generic
Tickers: PCRX, VRTX
Executed On: Aug 29, 2024 at 01:30 PM EDT -
Discussing Vertex Pharmaceticals' results from the ongoing phase 1/2 study of VX-880 for the treatment of Type 1 Diabetes presented at the American Diabetes Association 84th Scientific Sessions
Ticker: VRTX
Executed On: Jul 12, 2024 at 01:00 PM EDT -
A Third Look: Discussing prime editing, how it compares to CRISPR/Cas9, and it's potential in future therapeutics.
Tickers: PRME, VRTX, CRSP
Executed On: Jun 21, 2024 at 09:00 AM EDT -
A Second Look: Discussing prime editing, how it compares to CRISPR/Cas9, and it's potential in future therapeutics.
Tickers: PRME, VRTX, CRSP
Executed On: May 23, 2024 at 03:00 PM EDT -
Discussing prime editing, how it compares to CRISPR/Cas9, and it's potential in future therapeutics.
Tickers: PRME, VRTX, CRSP
Executed On: May 14, 2024 at 04:00 PM EDT -
A Third Look: Discussing the potential of gene therapies in SCD such as Vertex and CRISPR Therapeutics' CASGEVY (Exa-cel) and bluebird bio's LYFGENIA (lovotibeglogene autotemcel)
Tickers: VRTX, CRSP, BLUE
Executed On: May 02, 2024 at 02:00 PM EDT -
Follow-up Discussing how payers are strategizing pricing and reimbursement for cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease.
Tickers: VRTX, BLUE, CRSP
Executed On: May 02, 2024 at 10:00 AM EDT -
A Second Look: Discussing the potential of gene therapies in SCD such as Vertex and CRISPR Therapeutics' CASGEVY (Exa-cel) and bluebird bio's LYFGENIA (lovotibeglogene autotemcel)
Tickers: VRTX, CRSP, BLUE
Executed On: May 01, 2024 at 02:00 PM EDT -
Discussing the potential of gene therapies in SCD such as Vertex and CRISPR Therapeutics' CASGEVY (Exa-cel) and bluebird bio's LYFGENIA (lovotibeglogene autotemcel).
Tickers: VRTX, CRSP, BLUE
Executed On: Apr 24, 2024 at 12:00 PM EDT -
A Third Look: Discussing the potential of VX-548 for patients with Diabetic Peripheral Neuropathy.
Ticker: VRTX
Executed On: Feb 29, 2024 at 02:15 PM EST -
A Second Look: Discussing the potential of VX-548 for patients with Diabetic Peripheral Neuropathy.
Ticker: VRTX
Executed On: Feb 27, 2024 at 09:00 AM EST -
Discussing the potential of VX-548 for patients with Diabetic Peripheral Neuropathy.
Ticker: VRTX
Executed On: Feb 26, 2024 at 02:00 PM EST -
A third look at the potential of Vertex Phamaceuticals' “Vanza Triple” (vanzacaftor/tezacaftor/deutivacaftor) in patients with cystic fibrosis
Ticker: VRTX
Executed On: Feb 21, 2024 at 03:00 PM EST -
A Second Look: Digging into the results from the phase 3 study of VX-548 for the treatment of acute pain
Ticker: VRTX
Executed On: Feb 20, 2024 at 02:00 PM EST -
A second look at the potential of Vertex Phamaceuticals' “Vanza Triple” (vanzacaftor/tezacaftor/deutivacaftor) in patients with cystic fibrosis
Ticker: VRTX
Executed On: Feb 20, 2024 at 08:00 AM EST -
A look at the potential of Vertex Phamaceuticals' “Vanza Triple” (vanzacaftor/tezacaftor/deutivacaftor) in patients with cystic fibrosis
Ticker: VRTX
Executed On: Feb 09, 2024 at 12:00 PM EST -
Digging into the results from the phase 3 study of VX-548 for the treatment of acute pain
Ticker: VRTX
Executed On: Jan 30, 2024 at 11:15 AM EST -
A Second Look: Discussing how payers are strategizing pricing and reimbursement for recently approved cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease.
Tickers: VRTX, BLUE, CRSP
Executed On: Dec 21, 2023 at 01:00 PM EST -
Discussing how payers are strategizing pricing and reimbursement for recently approved cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease.
Tickers: VRTX, BLUE, CRSP
Executed On: Dec 19, 2023 at 01:00 PM EST -
A Second Look: Understanding the potential of Vertex Pharmaceutical's islet cell therapyVX-880 for treating type-1 diabetes.
Ticker: VRTX
Executed On: Oct 27, 2023 at 10:00 AM EDT -
Understanding the potential of Vertex Pharmaceutical's islet cell therapyVX-880 for treating type-1 diabetes.
Ticker: VRTX
Executed On: Oct 13, 2023 at 02:00 PM EDT -
A Third Look: Discussing the potential of Vertex Therapeutic's VX-548 as a non-opioid treatment for acute pain following a bunionectomy or abdominoplasty
Ticker: VRTX
Executed On: Sep 20, 2023 at 08:20 AM EDT -
A Second Look: Discussing the potential of Vertex Therapeutic's VX-548 as a non-opioid treatment for acute pain following a bunionectomy or abdominoplasty
Ticker: VRTX
Executed On: Sep 14, 2023 at 01:30 PM EDT -
A Second View - Prescriber Check In: The use of Provention Bio's Templizumab (Tzield) in delaying the onset of stage 3 type 1 diabetes in patients with stage 2 type 1 diabetes.
Tickers: PRVB, VRTX
Executed On: Sep 07, 2023 at 11:00 AM EDT -
An up to date look at exagamglogene autotemcel(exa-cel) in patients with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT)
Tickers: VRTX, CRSP, BLUE
Executed On: Sep 07, 2023 at 10:00 AM EDT -
Prescriber Check In: The use of Provention Bio's Templizumab (Tzield) in delaying the onset of stage 3 type 1 diabetes in patients with stage 2 type 1 diabetes.
Tickers: PRVB, VRTX
Executed On: Sep 06, 2023 at 05:30 PM EDT -
Discussing the potential of Vertex Therapeutic's VX-548 as a non-opioid treatment for acute pain following a bunionectomy or abdominoplasty
Ticker: VRTX
Executed On: Aug 23, 2023 at 09:00 AM EDT -
A second look: Discussing the potential of gene therapies such as exagamglogene autotemcel(exa-cel) in patients with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT)
Tickers: VRTX, CRSP, BLUE
Executed On: Apr 14, 2023 at 09:00 AM EDT -
A review of EDIT-301 as an experimental cell therapy medicine for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT)
Tickers: EDIT, VRTX, BLUE, CRSP
Executed On: Mar 13, 2023 at 02:00 PM EDT -
Discussing the potential of gene therapies such as exagamglogene autotemcel(exa-cel) in patients with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT)
Tickers: VRTX, CRSP
Executed On: Feb 07, 2023 at 10:00 AM EST -
Reviewing the clinical landscape of cystic fibrosis
Ticker: VRTX
Executed On: Oct 03, 2022 at 01:00 PM EDT -
A third look at the potential use of VX-548 in treating patients with acute and neuropathic pain
Tickers: VRTX, HRTX
Executed On: Sep 08, 2022 at 11:00 AM EDT -
A second look: Examining Provention Bio's Teplizumab as a new treatment to delay onset of clinical Type 1 Diabetes Mellitus
Tickers: PRVB, VRTX
Executed On: Aug 29, 2022 at 11:30 AM EDT -
A second look at the potential use of VX-548 in treating patients with acute and neuropathic pain
Ticker: VRTX
Executed On: Aug 19, 2022 at 12:00 PM EDT -
A look at the potential use of VX-548 in treating patients with acute and neuropathic pain
Ticker: VRTX
Executed On: Aug 03, 2022 at 05:00 PM EDT -
A Second look at Type 1 Diabetes and the VX-880 Clinical Trial data
Ticker: VRTX
Executed On: Jul 26, 2022 at 10:00 AM EDT -
A look at Type 1 Diabetes and the VX-880 Clinical Trial data
Ticker: VRTX
Executed On: Jul 18, 2022 at 03:00 PM EDT -
A Final look - Sickle Cell Update | New gene editing data from EHA 2022
Tickers: CRSP, VRTX
Executed On: Jun 28, 2022 at 12:45 PM EDT -
A second look - Sickle Cell Update | New gene editing data from EHA 2022
Tickers: CRSP, VRTX
Executed On: Jun 16, 2022 at 05:30 PM EDT -
Sickle Cell Update | New gene editing data from EHA 2022
Tickers: CRSP, VRTX
Executed On: Jun 15, 2022 at 04:30 PM EDT -
A Third view: Discussing VX-548, to be a first-in-class non-opioid treatment for acute pain in bunionectomy and abdominoplasty
Ticker: VRTX
Executed On: May 20, 2022 at 08:00 AM EDT -
A Second view: Discussing VX-548, to be a first-in-class non-opioid treatment for acute pain in bunionectomy and abdominoplasty
Ticker: VRTX
Executed On: Apr 27, 2022 at 10:30 AM EDT -
Discussing VX-548, to be a first-in-class non-opioid treatment for acute pain in bunionectomy and abdominoplasty.
Ticker: VRTX
Executed On: Apr 14, 2022 at 04:00 PM EDT
Upcoming & Overdue Catalysts (VRTX)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (VRTX)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
